Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Gastrointestinal Oncology and Mucosal Immunology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ZG16B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ZG16B Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View ZG16B Products |
| Gene Delivery | ZG16B Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View ZG16B Products |
| Benchmark Ab | Anti-ZG16B Recombinant Antibody Recombinant positive control for assay validation. |
View ZG16B Products |
| Validator | ZG16B siRNA Set For knockdown verification in functional assays. |
View ZG16B Products |
| Related Target A | ZG16 Highly homologous family member. Essential for off-target counter-screening. |
View ZG16 Products |
| Related Target B | MUC5AC Functional partner in mucosal barrier and cancer mucin interaction. |
View MUC5AC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily off-target cross-reactivity (ZG16 vs ZG16B) | Homolog panel proteins (ZG16 and ZG16B) strictly verified by mass spectrometry and sequence analysis. |
| Glycan-binding conformation preservation | HEK293 mammalian expression host ensures native glycosylation and correct folding of the Jacalin-like lectin domain. |
| Lack of Controls | Recombinant Benchmark Antibodies included for binding and functional assay calibration. |
| False Positives | Sequence-verified siRNA sets included for target-specific knockdown validation. |
Live ZG16B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ZG16B therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific constructs targeting gastrointestinal malignancies. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly specific epitope differentiation to avoid cross-reactivity with the highly homologous ZG16 protein, while exploiting ZG16B's unique expression profile in pancreatic and colon cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Biotech Startups, Global Pharma | Pancreatic Cancer, Colorectal Cancer | Internalization Assay (Need high-purity, natively glycosylated ZG16B antigen) |
| Bispecific Antibody | Oncology Biopharma | Gastrointestinal Tumors | Dual-targeting validation (Need cross-reactive and subfamily-specific control proteins) |
| Diagnostic / IHC mAbs | In Vitro Diagnostics (IVD) Companies | Cancer Biomarker Screening | High-specificity screening (Need ZG16 vs ZG16B counter-screening panel) |